Derfogail Delcassian

Derfogail Delcassian

Auto-generated profile, based on publicly available information

Derfogail Delcassian

Department of Bioengineering

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2019 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
LMLei Miao
Lei Miao
LLLinxian Li
Linxian Li
YHYuxuan Huang
Yuxuan Huang
DDDerfogail Delcassian
Derfogail Delcassian
JCJasdave Chahal
Jasdave Chahal
DADaniel G. Anderson
Daniel G. Anderson

15 May 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
LMLei Miao
Lei Miao
JLJiaqi Lin
Jiaqi Lin
YHYuxuan Huang
Yuxuan Huang
LLLinxian Li
Linxian Li
DDDerfogail Delcassian
Derfogail Delcassian
DADaniel G. Anderson
Daniel G. Anderson
Lipid-like nanoparticles (LNPs) have potential as non-viral delivery systems for mRNA therapies. However, repeated administrations of LNPs may lead to accumulation of delivery materials and associated toxicity. To address this challenge, we have developed biodegradable lipids which improve LNPs clearance and reduce toxicity. We modify the backbone structure of Dlin-MC3-DMA by introducing alkyne and ester groups into the lipid tails. We evaluate the performance of these lipids when co-formulated with other amine containing lipid-like materials. We demonstrate that these formulations synergistically facilitate robust mRNA delivery with improved tolerability after single and repeated administrations. We further identify albumin-associated macropinocytosis and endocytosis as an ApoE-independent LNP cellular uptake pathway in the liver. Separately, the inclusion of alkyne lipids significantly increases membrane fusion to enhance mRNA release, leading to synergistic improvement of mRNA delivery. We believe that the rational design of LNPs with multiple amine-lipids increases the material space for mRNA delivery.

1 August 2019 in Molecular Therapy
Verified
Journal Article
Open access
YRYulia Rybakova
Yulia Rybakova
PKPiotr S. Kowalski
Piotr S. Kowalski
YHYuxuan Huang
Yuxuan Huang
JGJohn T. Gonzalez
John T. Gonzalez
MHMichael W. Heartlein
Michael W. Heartlein
DADaniel G. Anderson
Daniel G. Anderson
Antibody-based drugs are a leading class of biologics used to treat a variety of diseases, including cancer. However, wide antibody implementation is hindered by manufacturing challenges and high production cost. Use of in-vitro-transcribed mRNA (IVT-mRNA) for endogenous protein expression has the potential to circumvent many of the shortcomings of antibody production and therapeutic application. Here, we describe the development of an IVT-mRNA system for in vivo delivery of a humanized anti-HER2 (also known as ERBB2) antibody, trastuzumab, and demonstrate its anticancer activity. We engineered the IVT-mRNA sequence to maximize expression, then formulated the IVT-mRNA into lipid-based nanoparticles (LNPs) to protect the mRNA from degradation and enable efficient in vivo delivery. Systemic delivery of the optimized IVT-mRNA loaded into LNPs resulted in antibody serum concentrations of 45 ± 8.6 μg/mL for 14 days after LNP injection. Further studies demonstrated an improved pharmacokinetic profile of the produced protein compared to injection of trastuzumab protein. Finally, treatment of tumor-bearing mice with trastuzumab IVT-mRNA LNPs selectively reduced the volume of HER2-positive tumors and improved animal survival. Taken together, the results of our study demonstrate that using IVT-mRNA LNPs to express full-size therapeutic antibodies in the liver can provide an effective strategy for cancer treatment and offers an alternative to protein administration.

21 October 2013 in Nano Letters
Verified
Journal Article
Closed access
DDDerfogail Delcassian
Derfogail Delcassian
DDDavid Depoil
David Depoil
DRDominika Rudnicka
Dominika Rudnicka
MLMengling Liu
Mengling Liu
DDDaniel M. Davis
Daniel M. Davis
IDIain E. Dunlop
Iain E. Dunlop

27 August 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
XSXinzhu Shan
Xinzhu Shan
ZZZhiqiang Zhao
Zhiqiang Zhao
PLPingping Lai
Pingping Lai
YLYuxiu Liu
Yuxiu Liu
BLBuyao Li
Buyao Li
LMLei Miao
Lei Miao
Metabolic dysfunction-associated steatohepatitis (MASH) poses challenges for targeted delivery and retention of therapeutic proteins due to excess extracellular matrix (ECM). Here we present a new approach to treat MASH, termed “Fibrosis overexpression and retention (FORT)”. In this strategy, we design (1) retinoid-derivative lipid nanoparticle (LNP) to enable enhanced mRNA overexpression in fibrotic regions, and (2) mRNA modifications which facilitate anchoring of therapeutic proteins in ECM. LNPs containing carboxyl-retinoids, rather than alcohol- or ester-retinoids, effectively deliver mRNA with over 10-fold enhancement of protein expression in fibrotic livers. The carboxyl-retinoid rearrangement on the LNP surface improves protein binding and membrane fusion. Therapeutic proteins are then engineered with an endogenous collagen-binding domain. These fusion proteins exhibit increased retention in fibrotic lesions and reduced systemic toxicity. In vivo, fibrosis-targeting LNPs encoding fusion proteins demonstrate superior therapeutic efficacy in three clinically relevant male-animal MASH models. This approach holds promise in fibrotic diseases unsuited for protein injection.

20 February 2018 in Journal of Drug Targeting
Verified
Journal Article
Closed access
DDDerfogail Delcassian
Derfogail Delcassian
Asha Kumari PatelAsha Kumari Patel
Asha Kumari Patel
ACAbel B. Cortinas
Abel B. Cortinas
RLRobert Langer
Robert Langer
Over the last century, there has been a dramatic change in the nature of therapeutic, biologically active molecules available to treat disease. Therapies have evolved from extracted natural products towards rationally designed biomolecules, including small molecules, engineered proteins and nucleic acids. The use of potent drugs which target specific organs, cells or biochemical pathways, necessitates new tools which can enable controlled delivery and dosing of these therapeutics to their biological targets. Here, we review the miniaturisation of drug delivery systems from the macro to nano-scale, focussing on controlled dosing and controlled targeting as two key parameters in drug delivery device design. We describe how the miniaturisation of these devices enables the move from repeated, systemic dosing, to on-demand, targeted delivery of therapeutic drugs and highlight areas of focus for the future.